14 results on '"Pang, Yizhen"'
Search Results
2. SSTR antagonist [68Ga]Ga-DOTA-LM3 differentiates intrapancreatic accessory spleen from neuroendocrine tumor in a patient presenting indeterminate MRI and SSTR agonist [68Ga]Ga-DOTATATE
- Author
-
Xu, Weizhi, Cai, Jiayu, Meng, Tinghua, Pang, YiZhen, and Chen, Haojun
- Published
- 2024
- Full Text
- View/download PDF
3. Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study
- Author
-
Guo, Wei, Wen, Xuejun, Chen, Yuhang, Zhao, Tianzhi, Liu, Jia, Tao, Yucen, Fu, Hao, Wang, Hongjian, Xu, Weizhi, Pang, Yizhen, Zhao, Liang, Huang, Jingxiong, Xu, Pengfei, Guo, Zhide, Miao, Weibing, Zhang, Jingjing, Chen, Xiaoyuan, and Chen, Haojun
- Published
- 2024
- Full Text
- View/download PDF
4. Application, challenge and development trend of machine learning in oil and gas field development.
- Author
-
YAN Chunming, CHEN Kongquan, LI Hongyan, LU Shengyan, WANG Yanfeng, and PANG Yizhen
- Subjects
GAS fields ,PETROLEUM prospecting ,OIL fields ,MACHINE learning ,DEEP learning - Abstract
With the continuous surge of production data in the field of oil exploration and development, the difficulty of integration and analysis is increasing, and manual analysis methods are difficult to meet the development needs of oil and gas fields on site. Machine learning can accurately and efficiently process data, and is a key technology in the field of data analysis and optimization. Utilizing machine learning to solve difficult problems in oil and gas field development has become the main focus of the industry. However, due to limitations in standardization construction, sample library establishment, and on-site integration, there are still many challenges and shortcomings in the application of machine learning in the field of oil exploration and development. In the future, efforts should be made to strengthen the standardization construction of machine learning, improve the data processing ability of deep learning algorithms, and pro-mote interdisciplinary research in the field of deep machine learning. Through multiple approaches, we can jointly promote the significant development of machine learning in the oil and gas field industry. [ABSTRACT FROM AUTHOR]
- Published
- 2024
5. Enhanced Detection of Early Pulmonary Fibrosis Disease Using 68Ga-FAPI-LM3 PET.
- Author
-
Chen, Jianhao, Luo, Doudou, Dai, Yaqing, Zhou, Yangfan, Pang, Yizhen, Wu, Hua, Sun, Long, Su, Guoqiang, Lin, Qin, Zhao, Liang, and Chen, Haojun
- Published
- 2024
- Full Text
- View/download PDF
6. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade.
- Author
-
Zhao, Liang, Pang, Yizhen, Zhou, Yangfan, Chen, Jianhao, Fu, Hao, Guo, Wei, Xu, Weizhi, Xue, Xin, Su, Guoqiang, Sun, Long, Wu, Hua, Zhang, Jingjing, Wang, Zhanxiang, Lin, Qin, Chen, Xiaoyuan, and Chen, Haojun
- Published
- 2024
- Full Text
- View/download PDF
7. Design, Preclinical Evaluation, and Clinical Translation of68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma
- Author
-
Zhao, Liang, primary, Pang, Yizhen, additional, Fang, Jianyang, additional, Chen, Jianhao, additional, Zhou, Yangfan, additional, Sun, Long, additional, Wu, Hua, additional, Guo, Zhide, additional, Lin, Qin, additional, and Chen, Haojun, additional
- Published
- 2024
- Full Text
- View/download PDF
8. SSTR antagonist [68Ga]Ga-DOTA-LM3 differentiates intrapancreatic accessory spleen from neuroendocrine tumor in a patient presenting indeterminate MRI and SSTR agonist [68Ga]Ga-DOTATATE.
- Author
-
Xu, Weizhi, Cai, Jiayu, Meng, Tinghua, Pang, YiZhen, and Chen, Haojun
- Subjects
NEUROENDOCRINE tumors ,SPLEEN ,MAGNETIC resonance imaging ,COMPUTED tomography - Abstract
A 46-year-old woman presented with upper abdominal pain and was initially suspected to have a pancreatic neuroendocrine tumor (NET) based on MRI signs. However, a SSTR2-targeted PET/CT scan using [68Ga]Ga-DOTATATE showed intense radiotracer uptake in the pancreatic nodule, similar to the adjacent spleen. To further differentiate between the two, a [68Ga]Ga-DOTA-LM3 PET/CT scan was performed, which showed no increased uptake in the pancreatic nodule, indicating a lower likelihood of neoplasia. A laparoscopic distal pancreatectomy confirmed the presence of an intrapancreatic accessory spleen (IPAS). This case highlights the challenges in differentiating pancreatic NETs from IPAS and suggests that [68Ga]Ga-DOTA-LM3 PET/CT may be helpful in making this distinction. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
9. Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma.
- Author
-
Chen, Jianhao, Pang, Yizhen, Liao, Xiyi, Zhou, Yangfan, Luo, Qicong, Wu, Hua, Zuo, Changjing, Zhang, Jingjing, Lin, Qin, Chen, Xiaoyuan, Zhao, Liang, and Chen, Haojun
- Subjects
- *
SOMATOSTATIN receptors , *PEPTIDE receptors , *POSITRON emission tomography , *NASOPHARYNX cancer , *NEUROENDOCRINE tumors - Abstract
Purpose: Somatostatin Receptor 2 (SSTR2)-targeted radiopharmaceutical [68Ga]Ga-DOTATATE has potential advantages in the diagnosis of nasopharyngeal carcinoma (NPC). This study introduces a novel long-lasting SSTR2 analogue, LNC1010, based on DOTATATE, a truncated Evans blue-binding moiety, and a polyethylene-glycol linker. We hypothesised that peptide receptor radionuclide therapy (PRRT) is more effective with [177Lu]Lu-LNC1010 than with [177Lu]Lu-DOTATATE in treating metastatic NPC.We assessed binding characteristics of LNC1010 in vitro using C666-1 NPC cells and in-vivo pharmacokinetics of [68Ga]Ga/[177Lu]Lu-LNC1010 in C666-1 NPC xenografts
via PET and SPECT imaging, biodistribution studies, and PRRT, and compared them with [68Ga]Ga/[177Lu] Lu-labelled DOTATATE. Furthermore, a proof-of-concept approach for imaging and therapy was conducted in a patient with metastatic NPC.LNC1010 exhibited strong uptake and specific affinity for SSTR2 in C666-1 NPC cells. PET and SPECT imaging demonstrated higher uptake and longer tumour retention of [68Ga]Ga/[177Lu]Lu-LNC1010 than [68Ga]Ga/[177Lu]Lu-DOTATATE in C666-1 NPC xenografts, indicating its suitability for PRRT applications in NPCs. Biodistribution studies confirmed the higher uptake and prolonged retention of [177Lu]Lu-LNC1010 than [177Lu]Lu-DOTATATE. In preclinical PRRT studies, [177Lu]Lu-LNC1010 showed greater inhibition of tumour growth in C666-1 NPC xenografts than [177Lu]Lu-DOTATATE. In a subsequent pilot clinical study, PRRT with [177Lu]Lu-LNC1010 achieved favourable therapeutic and negligible side effects in a patient with metastatic NPC.[177Lu]Lu-LNC1010 demonstrated increased tumour uptake and prolonged retention in SSTR2-positive NPCs, with superior anti-tumour efficacy to that of [177Lu]Lu-DOTATATE in preclinical studies. These findings suggest that PRRT with [177Lu]Lu-LNC1010 is a promising treatment for advanced NPC, extending the clinical scope of PRRT beyond neuroendocrine tumours.Methods: Somatostatin Receptor 2 (SSTR2)-targeted radiopharmaceutical [68Ga]Ga-DOTATATE has potential advantages in the diagnosis of nasopharyngeal carcinoma (NPC). This study introduces a novel long-lasting SSTR2 analogue, LNC1010, based on DOTATATE, a truncated Evans blue-binding moiety, and a polyethylene-glycol linker. We hypothesised that peptide receptor radionuclide therapy (PRRT) is more effective with [177Lu]Lu-LNC1010 than with [177Lu]Lu-DOTATATE in treating metastatic NPC.We assessed binding characteristics of LNC1010 in vitro using C666-1 NPC cells and in-vivo pharmacokinetics of [68Ga]Ga/[177Lu]Lu-LNC1010 in C666-1 NPC xenograftsvia PET and SPECT imaging, biodistribution studies, and PRRT, and compared them with [68Ga]Ga/[177Lu] Lu-labelled DOTATATE. Furthermore, a proof-of-concept approach for imaging and therapy was conducted in a patient with metastatic NPC.LNC1010 exhibited strong uptake and specific affinity for SSTR2 in C666-1 NPC cells. PET and SPECT imaging demonstrated higher uptake and longer tumour retention of [68Ga]Ga/[177Lu]Lu-LNC1010 than [68Ga]Ga/[177Lu]Lu-DOTATATE in C666-1 NPC xenografts, indicating its suitability for PRRT applications in NPCs. Biodistribution studies confirmed the higher uptake and prolonged retention of [177Lu]Lu-LNC1010 than [177Lu]Lu-DOTATATE. In preclinical PRRT studies, [177Lu]Lu-LNC1010 showed greater inhibition of tumour growth in C666-1 NPC xenografts than [177Lu]Lu-DOTATATE. In a subsequent pilot clinical study, PRRT with [177Lu]Lu-LNC1010 achieved favourable therapeutic and negligible side effects in a patient with metastatic NPC.[177Lu]Lu-LNC1010 demonstrated increased tumour uptake and prolonged retention in SSTR2-positive NPCs, with superior anti-tumour efficacy to that of [177Lu]Lu-DOTATATE in preclinical studies. These findings suggest that PRRT with [177Lu]Lu-LNC1010 is a promising treatment for advanced NPC, extending the clinical scope of PRRT beyond neuroendocrine tumours.Results: Somatostatin Receptor 2 (SSTR2)-targeted radiopharmaceutical [68Ga]Ga-DOTATATE has potential advantages in the diagnosis of nasopharyngeal carcinoma (NPC). This study introduces a novel long-lasting SSTR2 analogue, LNC1010, based on DOTATATE, a truncated Evans blue-binding moiety, and a polyethylene-glycol linker. We hypothesised that peptide receptor radionuclide therapy (PRRT) is more effective with [177Lu]Lu-LNC1010 than with [177Lu]Lu-DOTATATE in treating metastatic NPC.We assessed binding characteristics of LNC1010 in vitro using C666-1 NPC cells and in-vivo pharmacokinetics of [68Ga]Ga/[177Lu]Lu-LNC1010 in C666-1 NPC xenograftsvia PET and SPECT imaging, biodistribution studies, and PRRT, and compared them with [68Ga]Ga/[177Lu] Lu-labelled DOTATATE. Furthermore, a proof-of-concept approach for imaging and therapy was conducted in a patient with metastatic NPC.LNC1010 exhibited strong uptake and specific affinity for SSTR2 in C666-1 NPC cells. PET and SPECT imaging demonstrated higher uptake and longer tumour retention of [68Ga]Ga/[177Lu]Lu-LNC1010 than [68Ga]Ga/[177Lu]Lu-DOTATATE in C666-1 NPC xenografts, indicating its suitability for PRRT applications in NPCs. Biodistribution studies confirmed the higher uptake and prolonged retention of [177Lu]Lu-LNC1010 than [177Lu]Lu-DOTATATE. In preclinical PRRT studies, [177Lu]Lu-LNC1010 showed greater inhibition of tumour growth in C666-1 NPC xenografts than [177Lu]Lu-DOTATATE. In a subsequent pilot clinical study, PRRT with [177Lu]Lu-LNC1010 achieved favourable therapeutic and negligible side effects in a patient with metastatic NPC.[177Lu]Lu-LNC1010 demonstrated increased tumour uptake and prolonged retention in SSTR2-positive NPCs, with superior anti-tumour efficacy to that of [177Lu]Lu-DOTATATE in preclinical studies. These findings suggest that PRRT with [177Lu]Lu-LNC1010 is a promising treatment for advanced NPC, extending the clinical scope of PRRT beyond neuroendocrine tumours.Conclusion: Somatostatin Receptor 2 (SSTR2)-targeted radiopharmaceutical [68Ga]Ga-DOTATATE has potential advantages in the diagnosis of nasopharyngeal carcinoma (NPC). This study introduces a novel long-lasting SSTR2 analogue, LNC1010, based on DOTATATE, a truncated Evans blue-binding moiety, and a polyethylene-glycol linker. We hypothesised that peptide receptor radionuclide therapy (PRRT) is more effective with [177Lu]Lu-LNC1010 than with [177Lu]Lu-DOTATATE in treating metastatic NPC.We assessed binding characteristics of LNC1010 in vitro using C666-1 NPC cells and in-vivo pharmacokinetics of [68Ga]Ga/[177Lu]Lu-LNC1010 in C666-1 NPC xenograftsvia PET and SPECT imaging, biodistribution studies, and PRRT, and compared them with [68Ga]Ga/[177Lu] Lu-labelled DOTATATE. Furthermore, a proof-of-concept approach for imaging and therapy was conducted in a patient with metastatic NPC.LNC1010 exhibited strong uptake and specific affinity for SSTR2 in C666-1 NPC cells. PET and SPECT imaging demonstrated higher uptake and longer tumour retention of [68Ga]Ga/[177Lu]Lu-LNC1010 than [68Ga]Ga/[177Lu]Lu-DOTATATE in C666-1 NPC xenografts, indicating its suitability for PRRT applications in NPCs. Biodistribution studies confirmed the higher uptake and prolonged retention of [177Lu]Lu-LNC1010 than [177Lu]Lu-DOTATATE. In preclinical PRRT studies, [177Lu]Lu-LNC1010 showed greater inhibition of tumour growth in C666-1 NPC xenografts than [177Lu]Lu-DOTATATE. In a subsequent pilot clinical study, PRRT with [177Lu]Lu-LNC1010 achieved favourable therapeutic and negligible side effects in a patient with metastatic NPC.[177Lu]Lu-LNC1010 demonstrated increased tumour uptake and prolonged retention in SSTR2-positive NPCs, with superior anti-tumour efficacy to that of [177Lu]Lu-DOTATATE in preclinical studies. These findings suggest that PRRT with [177Lu]Lu-LNC1010 is a promising treatment for advanced NPC, extending the clinical scope of PRRT beyond neuroendocrine tumours. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
10. Enhanced Detection of Early Pulmonary Fibrosis Disease Using 68Ga-FAPI-LM3 PET
- Author
-
Chen, Jianhao, Luo, Doudou, Dai, Yaqing, Zhou, Yangfan, Pang, Yizhen, Wu, Hua, Sun, Long, Su, Guoqiang, Lin, Qin, Zhao, Liang, and Chen, Haojun
- Abstract
Early detection of pulmonary fibrosis is a critical yet insufficiently met clinical necessity. This study evaluated the effectiveness of FAPI-LM3, a 68Ga-radiolabeled heterobivalent molecular probe that targets fibroblast activating protein (FAP) and somatostatin receptor 2 (SSTR2), in the early detection of pulmonary fibrosis, leveraging its potential for early disease identification. A bleomycin-induced early pulmonary fibrosis model was established in C57BL/6 mice for 7 days. FAP and SSTR2 expression levels were quantitatively assessed in human idiopathic pulmonary fibrosis lung tissue samples and bleomycin-treated mouse lung tissues by using western blotting, real-time quantitative PCR (RT-qPCR), and immunofluorescence techniques. The diagnostic performance of FAPI-LM3 was investigated by synthesizing monomeric radiotracers 68Ga-FAPI-46 and 68Ga-DOTA-LM3 alongside the heterobivalent probe 68Ga-FAPI-LM3. These imaging radiopharmaceuticals were used in small-animal PET to compare their uptake in fibrotic and normal lung tissues. Results indicated significant upregulation of FAP and SSTR2 at both RNA and protein levels in fibrotic lung tissues compared with that in normal controls. PET imaging demonstrated significantly enhanced uptake of the 68Ga-FAPI-LM3 probe in fibrotic lung tissues, with superior visual effects compared to monomeric tracers. At 60 min postinjection, early stage fibrotic tissues (day 7) demonstrated low-to-medium uptake of monomeric probes, including 68Ga-DOTA-LM3 (0.45 ± 0.04% ID/g) and 68Ga-FAPI-46 (0.78 ± 0.09% ID/g), whereas the uptake of the heterobivalent probe 68Ga-FAPI-LM3 (1.90 ± 0.10% ID/g) was significantly higher in fibrotic lesions than in normal lung tissue. Blockade experiments confirmed the specificity of 68Ga-FAPI-LM3 uptake, which was attributed to synergistic targeting of FAP and SSTR2. This study demonstrates the potential of 68Ga-FAPI-LM3 for early pulmonary fibrosis detection via molecular imaging, offering significant benefits over monomeric tracers 68Ga-FAPI-46 and 68Ga-DOTA-LM3. This strategy offers new possibilities for noninvasive and precise early detection of pulmonary fibrosis.
- Published
- 2024
- Full Text
- View/download PDF
11. Enhanced Detection of Early Pulmonary Fibrosis Disease Using 68 Ga-FAPI-LM3 PET.
- Author
-
Chen J, Luo D, Dai Y, Zhou Y, Pang Y, Wu H, Sun L, Su G, Lin Q, Zhao L, and Chen H
- Subjects
- Animals, Mice, Humans, Pulmonary Fibrosis diagnostic imaging, Pulmonary Fibrosis metabolism, Pulmonary Fibrosis chemically induced, Lung diagnostic imaging, Lung pathology, Lung metabolism, Male, Bleomycin, Endopeptidases metabolism, Disease Models, Animal, Female, Idiopathic Pulmonary Fibrosis diagnostic imaging, Idiopathic Pulmonary Fibrosis metabolism, Membrane Proteins metabolism, Serine Endopeptidases metabolism, Quinolines, Receptors, Somatostatin metabolism, Mice, Inbred C57BL, Gallium Radioisotopes, Positron-Emission Tomography methods, Radiopharmaceuticals pharmacokinetics, Radiopharmaceuticals chemistry
- Abstract
Early detection of pulmonary fibrosis is a critical yet insufficiently met clinical necessity. This study evaluated the effectiveness of FAPI-LM3, a
68 Ga-radiolabeled heterobivalent molecular probe that targets fibroblast activating protein (FAP) and somatostatin receptor 2 (SSTR2), in the early detection of pulmonary fibrosis, leveraging its potential for early disease identification. A bleomycin-induced early pulmonary fibrosis model was established in C57BL/6 mice for 7 days. FAP and SSTR2 expression levels were quantitatively assessed in human idiopathic pulmonary fibrosis lung tissue samples and bleomycin-treated mouse lung tissues by using western blotting, real-time quantitative PCR (RT-qPCR), and immunofluorescence techniques. The diagnostic performance of FAPI-LM3 was investigated by synthesizing monomeric radiotracers68 Ga-FAPI-46 and68 Ga-DOTA-LM3 alongside the heterobivalent probe68 Ga-FAPI-LM3. These imaging radiopharmaceuticals were used in small-animal PET to compare their uptake in fibrotic and normal lung tissues. Results indicated significant upregulation of FAP and SSTR2 at both RNA and protein levels in fibrotic lung tissues compared with that in normal controls. PET imaging demonstrated significantly enhanced uptake of the68 Ga-FAPI-LM3 probe in fibrotic lung tissues, with superior visual effects compared to monomeric tracers. At 60 min postinjection, early stage fibrotic tissues (day 7) demonstrated low-to-medium uptake of monomeric probes, including68 Ga-DOTA-LM3 (0.45 ± 0.04% ID/g) and68 Ga-FAPI-46 (0.78 ± 0.09% ID/g), whereas the uptake of the heterobivalent probe68 Ga-FAPI-LM3 (1.90 ± 0.10% ID/g) was significantly higher in fibrotic lesions than in normal lung tissue. Blockade experiments confirmed the specificity of68 Ga-FAPI-LM3 uptake, which was attributed to synergistic targeting of FAP and SSTR2. This study demonstrates the potential of68 Ga-FAPI-LM3 for early pulmonary fibrosis detection via molecular imaging, offering significant benefits over monomeric tracers68 Ga-FAPI-46 and68 Ga-DOTA-LM3. This strategy offers new possibilities for noninvasive and precise early detection of pulmonary fibrosis.- Published
- 2024
- Full Text
- View/download PDF
12. Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China.
- Author
-
Zhao L, Kang F, Pang Y, Fang J, Sun L, Wu H, Lan X, Wang J, and Chen H
- Subjects
- Animals, Humans, China, Endopeptidases, Positron-Emission Tomography, Radioactive Tracers, Membrane Proteins antagonists & inhibitors, Membrane Proteins metabolism, Neoplasms diagnostic imaging, Neoplasms radiotherapy, Translational Research, Biomedical
- Abstract
Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs) have recently emerged as a focal point in global nuclear medicine, underscored by their promising applications in cancer theranostics and the diagnosis of various nononcological conditions. This review offers an in-depth summary of the existing literature on the evolution and use of FAPI tracers in China, tracing their journey from preclinical to clinical research. Moreover, this review also assesses the diagnostic accuracy of FAPI PET for the most common cancers in China, analyzes its impact on oncologic management paradigms, and investigates the potential of FAP-targeted radionuclide therapy in patients with advanced or metastatic cancer. This review also summarizes studies using FAPI PET for nononcologic disorders in China. Thus, this qualitative overview presents a snapshot of China's engagement with FAPI tracers, aiming to guide future research endeavors., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)
- Published
- 2024
- Full Text
- View/download PDF
13. Design, Preclinical Evaluation, and Clinical Translation of 68 Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
- Author
-
Zhao L, Pang Y, Fang J, Chen J, Zhou Y, Sun L, Wu H, Guo Z, Lin Q, and Chen H
- Subjects
- Animals, Humans, Gallium Radioisotopes, Fluorodeoxyglucose F18, Nasopharyngeal Carcinoma diagnostic imaging, Tissue Distribution, Positron-Emission Tomography, Positron Emission Tomography Computed Tomography, Nasopharyngeal Neoplasms diagnostic imaging
- Abstract
Extensive research has been conducted on radiolabeled fibroblast activation protein (FAP) inhibitors (FAPIs) and p-Cl-Phe-cyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)d-Tyr-NH
2 (LM3) peptides for imaging of FAP and somatostatin receptor 2 (SSTR2)-positive tumors. In this study, we designed and synthesized a FAPI-LM3 heterobivalent molecule radiolabeled with68 Ga and evaluated its effectiveness in both tumor xenografts and patients with nasopharyngeal carcinoma (NPC). Methods: The synthesis of FAPI-LM3 was based on the structures of FAPI-46 and LM3. After radiolabeling with68 Ga, its dual-receptor-binding affinity was evaluated in vitro and in vivo. Preclinical studies, including small-animal PET and biodistribution evaluation, were conducted on HT-1080-FAP and HT-1080-SSTR2 tumor xenografts. The feasibility of68 Ga-FAPI-LM3 PET/CT in a clinical setting was evaluated in patients with NPC, and the results were compared with those of18 F-FDG. Results:68 Ga-FAPI-LM3 showed high affinity for both FAP and SSTR2. The tumor uptake of68 Ga-FAPI-LM3 was significantly higher than that of68 Ga-FAPI-46 and68 Ga-DOTA-LM3 in HT-1080-FAP-plus-HT-1080-SSTR2 tumor xenografts. In a clinical study involving 6 NPC patients,68 Ga-FAPI-LM3 PET/CT showed significantly higher uptake than did18 F-FDG in primary and metastatic lesions, leading to enhanced lesion detectability and tumor delineation. Conclusion:68 Ga-FAPI-LM3 exhibited FAPI and SSTR2 dual-receptor-targeting properties both in vitro and in vivo, resulting in improved tumor uptake and retention compared with that observed with monomeric68 Ga-FAPI and68 Ga-DOTA-LM3. This study highlights the clinical feasibility of68 Ga-FAPI-LM3 PET/CT for NPC imaging., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2024
- Full Text
- View/download PDF
14. Fibroblast Activation Protein-Targeted PET/CT with 18 F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18 F-FDG PET/CT.
- Author
-
Xu W, Cai J, Peng T, Meng T, Pang Y, Sun L, Wu H, Zhang J, Chen X, and Chen H
- Subjects
- Humans, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Prospective Studies, Positron-Emission Tomography, Fibroblasts, Gallium Radioisotopes, Stomach Neoplasms diagnostic imaging, Gastrointestinal Neoplasms diagnostic imaging, Pancreatic Neoplasms diagnostic imaging, Liver Neoplasms diagnostic imaging, Quinolines
- Abstract
Fibroblast activation protein is overexpressed in the stroma of several cancer types.
18 F-fibroblast activation protein inhibitor (FAPI)-74 is a PET tracer with high selectivity for fibroblast activation protein and has shown high accumulation in human tumors in clinical studies. However, the use of18 F-FAPI-74 for PET imaging of gastrointestinal cancer has not been systematically investigated. Herein, we investigated the diagnostic accuracy of18 F-FAPI-74 (18 F-LNC1005) PET/CT in gastric, liver, and pancreatic cancers and compared the results with those of18 F-FDG PET/CT. Methods: This prospective study analyzed patients with confirmed gastric, liver, or pancreatic malignancies who underwent concurrent18 F-FDG and18 F-FAPI-74 PET/CT between June 2022 and December 2022. PET/CT findings were confirmed by histopathology or radiographic follow-up.18 F-FDG and18 F-FAPI-74 uptake and tumor-to-background ratios were compared using the Wilcoxon signed-rank test. The McNemar test was used to compare the diagnostic accuracy of the 2 scans. Results: Our cohort consisted of 112 patients: 49 with gastric cancer, 39 with liver cancer, and 24 with pancreatic cancer. Among them, 69 patients underwent PET/CT for initial staging and 43 for recurrence detection. Regarding lesion-based diagnostic accuracy,18 F-FAPI-74 PET/CT showed higher sensitivity than did18 F-FDG in the detection of primary tumors (gastric cancer, 88% [22/25] vs. 60% [15/25], P = 0.016; liver cancer, 100% [22/22] vs. 82% [18/22], P = 0.125; pancreatic cancer, 100% [22/22] vs. 86% [19/22], P = 0.250), local recurrence (92% [23/25] vs. 56% [14/25]; P = 0.021), involved lymph nodes (71% [41/58] vs. 40% [23/58]; P < 0.001), and bone and visceral metastases (98% [350/358] vs. 47% [168/358]; P < 0.001). Compared with18 F-FDG,18 F-FAPI-74 PET/CT upstaged 17 patients' TNM staging among all treatment-naïve patients (17/69, 25%) and changed the clinical management of 4 patients (4/43, 9%) in whom recurrence or metastases were detected. Conclusion:18 F-FAPI-74 PET/CT is superior to18 F-FDG PET/CT in detecting primary tumors, local recurrence, lymph node involvement, and bone and visceral metastases in gastric, pancreatic, and liver cancers, with higher uptake in most primary and metastatic lesions., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.